Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 2
1968 1
1969 1
1971 1
1973 1
1975 3
1976 2
1977 1
1978 3
1979 2
1980 3
1981 3
1982 1
1983 2
1984 8
1985 8
1986 13
1987 8
1988 12
1989 12
1990 31
1991 20
1992 36
1993 29
1994 44
1995 30
1996 35
1997 54
1998 52
1999 76
2000 97
2001 88
2002 124
2003 163
2004 198
2005 230
2006 305
2007 345
2008 396
2009 407
2010 500
2011 577
2012 713
2013 786
2014 853
2015 894
2016 923
2017 1006
2018 1119
2019 1166
2020 1362
2021 1466
2022 1637
2023 1638
2024 806

Text availability

Article attribute

Article type

Publication date

Search Results

16,059 results

Results by year

Filters applied: . Clear all
Page 1
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q, Han J, Yang Y, Chen Y. Li Q, et al. Among authors: han j. Front Immunol. 2022 Dec 19;13:1070961. doi: 10.3389/fimmu.2022.1070961. eCollection 2022. Front Immunol. 2022. PMID: 36601120 Free PMC article. Review.
Programmed cell death ligand 1 (PDL-1) is involved in tumor immune evasion by binding to PD-1, resulting in failure of treatment. ...For most patients with HCC, the PD-1/PD-L1 pathway is not the only rate limiting factor of antitumor immunity, and bloc …
Programmed cell death ligand 1 (PDL-1) is involved in tumor immune evasion by binding to PD-1, resulting in failure of …
Risk factors for vancomycin-associated acute kidney injury: A systematic review and meta-analysis.
Kim JY, Yee J, Yoon HY, Han JM, Gwak HS. Kim JY, et al. Among authors: han jm. Br J Clin Pharmacol. 2022 Sep;88(9):3977-3989. doi: 10.1111/bcp.15429. Epub 2022 Jun 15. Br J Clin Pharmacol. 2022. PMID: 35665530 Free article. Review.
RESULTS: Fifty-three studies were included in our meta-analysis. For patient factors, black race (OR 1.47, 95% CI: 1.16-1.87), Caucasian (OR 0.72, 95% CI: 0.58-0.90) and obesity (OR 1.46, 95% CI: 1.12-1.90) were associated with an increas …
RESULTS: Fifty-three studies were included in our meta-analysis. For patient factors, black race (OR 1.47, 95% CI: 1.16-1 …
SQSTM1/p62 activates NFE2L2/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity.
Lee DH, Park JS, Lee YS, Han J, Lee DK, Kwon SW, Han DH, Lee YH, Bae SH. Lee DH, et al. Among authors: han j. Autophagy. 2020 Nov;16(11):1949-1973. doi: 10.1080/15548627.2020.1712108. Epub 2020 Jan 10. Autophagy. 2020. PMID: 31913745 Free PMC article.
Lipotoxicity, induced by saturated fatty acid (SFA)-mediated cell death, plays an important role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). The KEAP1 (kelch like ECH associated protein 1)-NFE2L2/NRF2 (nuclear factor, erythroid 2 like 2) pathway is a p …
Lipotoxicity, induced by saturated fatty acid (SFA)-mediated cell death, plays an important role in the pathogenesis of nonalcoholic fatty l …
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Wolf J, et al. Among authors: han jy. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. N Engl J Med. 2020. PMID: 32877583 Clinical Trial.
BACKGROUND: Among patients with non-small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET …
BACKGROUND: Among patients with non-small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications o …
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial.
Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB, Rha SW, Bae JW, Lee NH, Hur SH, Yoon J, Park TH, Kim BS, Lim SW, Cho YH, Jeon DW, Kim SH, Han JK, Shin ES, Kim HS; HOST-EXAM investigators. Koo BK, et al. Among authors: han jk. Lancet. 2021 Jun 26;397(10293):2487-2496. doi: 10.1016/S0140-6736(21)01063-1. Epub 2021 May 16. Lancet. 2021. PMID: 34010616 Clinical Trial.
We excluded patients with any ischaemic and major bleeding complications. Patients were randomly assigned (1:1) to receive a monotherapy agent of clopidogrel 75 mg once daily or aspirin 100 mg once daily for 24 months. ...
We excluded patients with any ischaemic and major bleeding complications. Patients were randomly assigned (1:1) to receive a m …
Role of brain NUCB2/nesfatin-1 in stress and stress-related gastrointestinal disorders.
Zheng J, Han J, Wang Y, Tian Z. Zheng J, et al. Among authors: han j. Peptides. 2023 Sep;167:171043. doi: 10.1016/j.peptides.2023.171043. Epub 2023 Jun 11. Peptides. 2023. PMID: 37311488 Review.
Since the discovery of NUCB2/nesfatin-1 as a novel anorexigenic factor, the expanding function of this peptide has been elucidated in recent years. Increasing evidence suggests that NUCB2/nesfatin-1 is also involved in the regulation of stress and stress-related gas …
Since the discovery of NUCB2/nesfatin-1 as a novel anorexigenic factor, the expanding function of this peptide has been elucidated in …
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Gong B, Yao Z, Zhou C, Wang W, Sun L, Han J. Gong B, et al. Among authors: han j. Eur J Med Chem. 2024 Apr 5;269:116342. doi: 10.1016/j.ejmech.2024.116342. Epub 2024 Mar 17. Eur J Med Chem. 2024. PMID: 38531211 Review.
Glucagon-like peptide-1 (GLP-1), secreted by L cells in the small intestine, assumes a central role in managing type 2 diabetes mellitus (T2DM) and obesity. ...To address this, various structural modification strategies have been developed to extend GLP-1's h …
Glucagon-like peptide-1 (GLP-1), secreted by L cells in the small intestine, assumes a central role in managing type 2 diabete …
2-Chloro-methyl-1-methyl-1,3-benzimidazole.
Han J, Zhang J, Yang Q, Zhao MG, Fan G. Han J, et al. Acta Crystallogr Sect E Struct Rep Online. 2011 Aug 1;67(Pt 8):o2104. doi: 10.1107/S1600536811028376. Epub 2011 Jul 23. Acta Crystallogr Sect E Struct Rep Online. 2011. PMID: 22091123 Free PMC article.
The title compound, C(9)H(9)ClN(2), was prepared from the reaction of N-methyl-benzene-1,2-diamine and 2-chloro-acetic acid in boiling 6 M hydro-chloric acid. The benzimidazole unit is approximately planar, the largest deviation from the mean plane being 0.008 (1) A …
The title compound, C(9)H(9)ClN(2), was prepared from the reaction of N-methyl-benzene-1,2-diamine and 2-chloro-acetic acid in boilin …
An updated patent review of GLP-1 receptor agonists (2020-present).
Lu W, Zhou Z, Jiang N, Han J. Lu W, et al. Among authors: han j. Expert Opin Ther Pat. 2023 Jul-Dec;33(9):597-612. doi: 10.1080/13543776.2023.2274905. Epub 2023 Nov 28. Expert Opin Ther Pat. 2023. PMID: 37870067 Review.
Patent searches were conducted using the PATENTSCOPE database of the World Intellectual Property Organization, using the keywords GLP-1, GLP-1/GIP, GLP-1/GCG, and GLP-1/GCG/GIP. EXPERT OPINION: In recent years, patents have emphasized two main goals fo …
Patent searches were conducted using the PATENTSCOPE database of the World Intellectual Property Organization, using the keywords GLP-1 …
16,059 results
You have reached the last available page of results. Please see the User Guide for more information.